Presentation by Pol Boudes, Chief Medical Officer, Galectin Therapeutics,USA

Innovating in NASH cirrhosis

Share this article:

Belapectin a complex carbohydrate drug the inhibits galectin-3

Belapectin, a galectin-3 (Gal-3) inhibitor, is in development for the prevention of esophageal varices in patients with NASH cirrhosis. Patients with cirrhosis need a therapeutic breakthrough as, currently, their only hope is a liver transplant.

Pol Boudes focuses here on to a phase 2 study looking at the perfomance of belapectin.